Navigation Links
Study Finds QIAGEN's HPV Test Offers Greater Long-term Protection From Cervical Disease Than the Pap
Date:5/21/2008

mmon malignancy found in women. Cervical cancer is caused by "high-risk" types of the human papillomavirus (HPV), which are sexually transmitted. It's estimated that 80 percent of women will get an HPV infection at some point in their lives. However, in most cases, the infection goes away or is suppressed by the body without causing problems. It is only infections that persist that can cause abnormal cells to form that may develop into cervical cancer if not detected and treated early. One report from the World Health Organization estimates that only about 5 percent of women had been screened for cervical disease in the previous five years, compared to 40-50 percent in the developed world.

About QIAGEN (http://www.qiagen.com)

QIAGEN NV, headquartered in the Netherlands, is the leading global provider of sample and assay technologies. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue, and assays make these isolated molecules visible to facilitate such vital activities as biological research and detection of disease. QIAGEN has developed and markets more than 500 products as well as instruments that make their use more efficient and accurate. The company provides its products to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes such as forensics, animal or food testing and pharmaceutical process control. QIAGEN's assay technologies include one of the broadest panels of molecular diagnostic tests available worldwide, including the only FDA-approved test for human papillomavirus (HPV), the primary cause of cervical cancer. QIAGEN employs more than 2,600 people in over 30 locations worldwide.

Pam Rasmussen Dr. Thomas Theuringer

QIAGEN Gaithersburg QIAGEN GmbH

+1-240-686-7616 +49-
'/>"/>

SOURCE Qiagen N V
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results
2. Safety and Efficacy Results Presented From Largest Prospective Controlled Clinical Study of Ulcerative Colitis
3. Annual FIT Testing Detects Colorectal Cancer Two Years Earlier Than Colonoscopy Alone, Study of High-Risk Population Finds
4. Study Analyzed SYMBICORT(R) in Children with Persistent Asthma
5. Omeros Announces Initiation of Patient Enrollment in OMS201 Phase 1 Study
6. BioMarin Initiates Phase 1 Clinical Study of PEG-PAL in PKU
7. Analysis of Ulcerative Colitis (UC) Time to Symptom Resolution Data from Pivotal Study of LIALDA(TM) (mesalamine) Presented at DDW
8. Elesclomol Study Shows Significant Improvement in Progression-Free Survival for Chemotherapy-Naive Patients With Metastatic Melanoma
9. Palatin Technologies Initiates Phase 2 Hypertension Clinical Study With PL-3994
10. Fuisz Tobacco Announces Clinical Study Results for Fuisz Tobacco Sheet Strip; Super Enhanced Bioavailability of Nicotine From Its Tobacco Sheet Strip Supports Efficacy of Low Dose Tobacco Product
11. Delcath Updates Phase III Patient Enrollment as Pivotal Trial Accelerates, Durable Tumor Responses In Phase II Study Also Cited
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... , April 17, 2015  In Detroit, where three out ... rate is two and one half times of the national ... of 10 infants that die in Detroit ... statistics that Covenant Community Care, a faith-based, charitable non-profit Community ... to change thanks to a charitable donation by Konica Minolta ...
(Date:4/17/2015)... 17, 2015 Steven Rash , the CEO ... its operating subsidiary American Seed & Oil Company, presented ... investors yesterday in New York City.  Mr. Rash,s presentation ... American Seed & Oil Company has recently announced the ... Hemp Seed Foods , the EpiVape , and ...
(Date:4/17/2015)... Apr. 16, 2015 Research and Markets ... of the "The Corporate Reputation of Pharma ... Edition " report to their offering. ... Perspective, is now in its fourth edition. This ... early 2015). For each annual Corporate Reputation report, ...
Breaking Medicine Technology:Covenant Community Care to Receive Donated SONIMAGE P3 Handheld Ultrasound from Konica Minolta Medical Imaging 2Covenant Community Care to Receive Donated SONIMAGE P3 Handheld Ultrasound from Konica Minolta Medical Imaging 3Covenant Community Care to Receive Donated SONIMAGE P3 Handheld Ultrasound from Konica Minolta Medical Imaging 4American Seed & Oil Company Benchmarks its Consumer Product Development Strategy Against Proctor & Gamble 2American Seed & Oil Company Benchmarks its Consumer Product Development Strategy Against Proctor & Gamble 3The Corporate Reputation of Pharma - The Global Patient Perspective in 2014 2
... Bioequivalence , LONDON, UK and ATLANTA, US, May ... Pharma. Inc. (NASDAQ:SCRX) today,announce the successful completion of ... Sular, a calcium ,channel blocking agent for the ... that the new Sular formulation is,bioequivalent to Sciele's ...
... from placebo,controlled phase IIa study in patients ... (Zurich), Switzerland, May 15, 2007 - Cytos ... a multi-centre,and placebo-controlled phase IIa study with ... for the,treatment of allergic diseases. The study ...
Cached Medicine Technology:SkyePharma and Sciele Pharma Announce Successful Completion of New,Sular Formulation Clinical Trial Programme 2SkyePharma and Sciele Pharma Announce Successful Completion of New,Sular Formulation Clinical Trial Programme 3Positive results from placebo-controlled phase IIa study in,patients suffering from house dust mite allergy 2Positive results from placebo-controlled phase IIa study in,patients suffering from house dust mite allergy 3Positive results from placebo-controlled phase IIa study in,patients suffering from house dust mite allergy 4Positive results from placebo-controlled phase IIa study in,patients suffering from house dust mite allergy 5Positive results from placebo-controlled phase IIa study in,patients suffering from house dust mite allergy 6Positive results from placebo-controlled phase IIa study in,patients suffering from house dust mite allergy 7
(Date:4/17/2015)... (PRWEB) April 17, 2015 At the ... EcoLuxe Lounge and the “Salute to the Oscars” in ... Beverly Hilton Hotel, overlooking the impressive Los Angeles skyline. ... organized by Debbie Durkin, LA’s leading producer of sustainable ... many of the world’s premier providers of eco-friendly and ...
(Date:4/17/2015)... 17, 2015 Baptist Health and The ... a partnership agreement designed to transform oncology care in ... have agreed to create a joint cancer program to ... translational research. Baptist MD Anderson Cancer Center is anticipated ... single destination for highly coordinated, multidisciplinary cancer care for ...
(Date:4/17/2015)... The American College of Traditional Chinese Medicine (ACTCM) is ... April 29. The event will be held from 11 a.m. to ... St. in San Francisco, CA. , The agenda for the day ... DeHaro campus (room F), 11:10 a.m. – Introduction and welcome ... lunch with current students, faculty and staff, 1 p.m. – Observe ...
(Date:4/17/2015)... Compare-autoinsurance.org has released a new blog post ... insurance quotes . , The online environment can ... cars. Drivers should always compare multiple car insurance policies ... is a competitive one, which means that customers can ... It is now possible to compare online car insurance ...
(Date:4/17/2015)... released a new blog post explaining the dangers of sleeping ... rates . , Falling asleep at the wheel can ... impact on auto insurance prices. The premiums will go up ... newly released blog post talks more about drowsiness at the ... is now possible to find low cost car insurance plans ...
Breaking Medicine News(10 mins):Health News:Choices Recovery Speaks with Dakota Hood of “The Hunger Games” about Addiction in Hollywood 2Health News:Baptist Health and MD Anderson Finalize Agreement to Transform Cancer Care in Region 2Health News:Baptist Health and MD Anderson Finalize Agreement to Transform Cancer Care in Region 3Health News:American College of Traditional Chinese Medicine Hosts Open House 2Health News:The Best Auto Insurance Quotes Are Available Online! 2Health News:Accidents Caused By Sleeping at The Wheel Can Increase Auto Insurance Costs 2
... help avoid treatment toxicity, research shows , WEDNESDAY, Sept. ... researchers may have found a better way for them ... , A regimen using antibodies instead of high-dose ... to Dr. Persis J. Amrolia, a doctor in the ...
... , ROCHESTER, N.Y., Sept. 2 "Everyone ... flu virus. Let me tell you about my personal encounter ... article on Dr. Hanan Polansky,s book, where he describes his ... After I read the article, I started taking Gene-Eden, a ...
... Agreement to Sell MDS Analytical Technologies to Danaher, ... Shareholders;, Announces Intent to Sell MDS Pharma Services, ... MDS; NYSE: MDZ ), a leading provider of products ... it has entered into an agreement to sell its MDS Analytical ...
... , , ... (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), Gurgaon, ... and distribute an authorized generic version of Rocaltrol(R) (calcitriol) in both ... for calcitriol softgel capsules and oral liquid were $70 million (IMS ...
... , THE WOODLANDS, Texas, Sept. 2 ... LXRX ), a biopharmaceutical company focused on discovering and developing breakthrough ... Sands, M.D., Ph.D. , Lexicon,s president and chief executive officer, ... Four Seasons Hotel in Boston, Massachusetts on Wednesday, September 9, 2009 ...
... ... bill compliance auditing, today announced their partnership with Pat Palmer, President and Founder of ... of whom are pioneers in the field of medical bill advocacy. , ... Boca Raton, FL (PRWEB) September ...
Cached Medicine News:Health News:New Technique Offers Hope for Kids With Immune Deficiency 2Health News:How to Protect Against the Swine Flu Virus: 'My Personal Experience with Gene-Eden(TM), a Broad Range Antiviral Supplement' 2Health News:MDS Announces Strategic Repositioning 2Health News:MDS Announces Strategic Repositioning 3Health News:MDS Announces Strategic Repositioning 4Health News:MDS Announces Strategic Repositioning 5Health News:MDS Announces Strategic Repositioning 6Health News:MDS Announces Strategic Repositioning 7Health News:MDS Announces Strategic Repositioning 8Health News:MDS Announces Strategic Repositioning 9Health News:Ranbaxy Launches Authorized Generic Version of Rocaltrol(R) 2Health News:Ranbaxy Launches Authorized Generic Version of Rocaltrol(R) 3Health News:Lexicon Pharmaceuticals to Present at the Thomas Weisel Partners Healthcare Conference 2Health News:TrueFACS Announces the Addition of Nora Johnson and Pat Palmer of Medical Billing Advocates of America 2
Produce clean 0.75 mm round hole without tissue tags. Serrated squeeze action handle....
Brightness acuity tester....
Stainless steel flexible ruler. graduated in 1/32 inches (.8 mm) fractions, as well as mm graduations....
Measures up to 152 mm in 1 mm increments and 6 inches in 1/32 inch increments. Deeply etched graduations and dull finish....
Medicine Products: